Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|July 5, 2022
[Corporate Efforts to Research and Develop Therapeutic Agents for Infectious Diseases That Threaten Human]Ryu Yoshida, Rina Kaki, Osamu Yoshida, et al.Journal of Pharmaceutical Sciences|July 28, 2006
High throughput solubility measurement with automated polarized light microscopy analysisKiyohiko Sugano, Teruhisa Kato, Kentaro Suzuki, et al.ACS Infectious Diseases|November 19, 2024
Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing CompoundsTakaya Sakura, Ryuta Ishii, Eri Yoshida, et al.Archives of Environmental Contamination and Toxicology|January 9, 2008
Aryl hydrocarbon receptor and estrogen receptor ligand activity of organic extracts from road dust and diesel exhaust particulatesKentaro Misaki, Masato Suzuki, Masafumi Nakamura, et al.Viruses|October 28, 2023
Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse ModelKeita Fukao, Haruaki Nobori, Takayuki Kuroda, et al.Biochemical and Biophysical Research Communications|January 23, 2023
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globallySho Kawashima, Yuki Matsui, Takumi Adachi, et al.Antiviral Research|March 1, 2024
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2Haruaki Nobori, Keiko Baba, Takayuki Kuroda, et al.Life Sciences|February 1, 2005
Anti-thyroid hormonal activity of tetrabromobisphenol A, a flame retardant, and related compounds: Affinity to the mammalian thyroid hormone receptor, and effect on tadpole metamorphosisShigeyuki Kitamura, Teruhisa Kato, Mitsuru Iida, et al.Antiviral Research|October 30, 2024
Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission modelMasaaki Nakashima, Haruaki Nobori, Takayuki Kuroda, et al.The Journal of Pharmacology and Experimental Therapeutics|November 5, 2008
N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux diseaseHiroki Mori, Hiroko Tonai-Kachi, Yasuo Ochi, et al.Pageof 2